Skerjanec Simona 4
4 · Atrium Therapeutics, Inc. · Filed Mar 2, 2026
Research Summary
AI-generated summary of this filing
Atrium Therapeutics (RNA) Director Simona Skerjanec Receives Award
What Happened
Simona Skerjanec, a director of Atrium Therapeutics, was granted 20,000 equity awards (reported as a derivative award) on February 27, 2026. The filing shows a price of $0.00 and total reported value of $0 at grant — this reflects a compensation award (transaction code "A"), not a cash purchase or sale.
Key Details
- Transaction date: 2026-02-27 (reported on Form 4 filed 2026-03-02). Filing appears timely.
- Transaction type/code: Award/Grant (A) of 20,000 derivative shares; reported price per share = $0.00; reported total value = $0.
- Vesting: The award vests in equal monthly installments over the three years following the grant date, subject to continuous service. (Footnote F1)
- Shares owned after transaction: Not specified in the provided summary of the filing.
- Insider role: Director (not listed as a 10% owner or executive in this summary).
Context
This was a compensation grant (equity award) rather than an open-market purchase or sale. Such grants are common for board compensation and do not involve immediate cash outlay; the awards become economically meaningful only as they vest and/or are exercised according to plan terms. The filing does not indicate any immediate sale or cashless exercise.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-02-27+20,000→ 20,000 totalExercise: $14.75Exp: 2036-02-27→ Common Stock (20,000 underlying)
Footnotes (1)
- [F1]The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.